5 Most Promising Biotech Stocks According to Analysts
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) was founded in 2008 and is headquartered in Boston, Massachusetts.
Vir Biotechnology Inc. (VIR)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Point72 Asset Management Steve Cohen | 1,683,100 | $39,165,737 | 0.12% | |
| 2. | Avidity Partners Management David Witzke And Michael Gregory | 1,640,200 | $38,167,454 | +93% | 1.26% |
| 3. | Braidwell LP Alex Karnal | 604,036 | $14,055,918 | 0.46% | |
| 4. | Balyasny Asset Management Dmitry Balyasny | 402,948 | $9,376,600 | 0.02% | |
| 5. | AQR Capital Management Cliff Asness | 337,672 | $7,857,627 | +10% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.73 | 2,500 | Director | 10,000 | 2023-03-01 | Filing | |
| $24.96 | 2,500 | Director | 7,500 | 2023-01-05 | Filing | |
| $25.25 | 2,500 | Director | 5,000 | 2023-01-04 | Filing | |
| $25.60 | 2,500 | Director | 2,500 | 2023-01-03 | Filing | |
| $43.39 | 12 | Officer | 12 | 2021-11-29 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $27.12 | 2,323 | Large Shareholder | 17,178,585 | 2023-05-24 | Filing | |
| $26.25 | 66,754 | Large Shareholder | 17,180,908 | 2023-05-24 | Filing | |
| $25.89 | 35,307 | Large Shareholder | 17,247,662 | 2023-05-24 | Filing | |
| $27.02 | 23,348 | Large Shareholder | 17,282,969 | 2023-05-23 | Filing | |
| $26.61 | 144,402 | Large Shareholder | 17,306,317 | 2023-05-23 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 18,319,938 | $426,304,957 | 3.5% | |
| 2. | 13,955,491 | $324,744,275 | 0% | |
| 3. | 10,267,462 | $238,923,841 | 0% | |
| 4. | 5,814,972 | $135,314,398 | 0.8% | |
| 5. | 5,384,163 | $125,289,304 | 0% |
News See All
5 High Growth Pharma Stocks that are Profitable
Halozyme Therapeutics, Inc. (NASDAQ:HALO)'s third quarter of 2022 results saw the firm bring in $209 million in revenue, which marked a strong 80% annual growth.
11 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
In this article, we will take a look at the 11 most undervalued biotech stocks to buy according to hedge funds.
10 Best Healthcare Stocks For the Long Term
The healthcare sector is one of those rare, evergreen areas of the industry that refuse to waver even when the entire market is shaking.
Hedge Fund and Insider Trading News: Jeffrey Ubben, Ken Griffin, Angelo Gordon & Co., Inclusive Capital Partners, Trium Capital LLP, Coinbase Global Inc (COIN), HP Inc. (HPQ), and More
New details are emerging on hedge fund billionaire Ken Griffin’s planned office skyscraper in Midtown.
11 Best Pharma and Biotech Stocks to Buy According to Jim Simons' Euclidean Capital
In this article, we will discuss the 11 best pharma and biotech stocks to buy according to Jim Simons' Euclidean Capital.
Is Vir Biotechnology (VIR) A Good Stock To Buy Now?
The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September...
Vir Biotechnology, Inc. (VIR): Hedge Funds Aren't Enthusiastic
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first.
Trumpdesivir: Operation Warp Speed, “Engage.”
The COVID-19 vaccine race officially goes into high gear with the announcement of USA’s plan to test the 6-odd top vaccine candidates across upwards of 150,000 volunteers (min.
Stocks Amid COVID-19 Outbreak: Winners So Far in the Health Industry
At its worst on March 23rd, Dow Jones and the S&P declined by around 37% and 34%. At the time, those kinds of numbers represented a loss of a 3-year gain since Trump’s election in November of 2016.
Billionaire Hedge Funds
